Prognostic factors and predictive models in renal cell carcinoma: A contemporary review

European Urology

Volumn 60, Issue 4, 2011, Pages 644-661

  Sun, Maxine ^a   Shariat, Shahrokh F ^b   Cheng, Christopher ^c   Ficarra, Vincenzo ^d   Murai, Masaru ^e   Oudard, Stéphane ^f   Pantuck, Allan J ^g   Zigeuner, Richard ^h   Karakiewicz, Pierre I ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d UNIVERSITY OF PADOVA   (Italy)

^e KEIO UNIVERSITY   (Japan)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Molecular marker; Predictive model; Prognostic factor; Renal cell carcinoma

Indexed keywords

ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; CALCIUM; CARBONATE DEHYDRATASE IX; CAVEOLIN 1; FASCIN; HEMOGLOBIN; INSULIN LIKE GROWTH FACTOR II MRNA BINDING PROTEIN 3; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; MEMBRANE PROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN KINASE B; PROTEIN P53; SERUM AMYLOID A; SOMATOMEDIN C; SUNITINIB; SURVIVIN; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN; VIMENTIN;

ALKALINE PHOSPHATASE BLOOD LEVEL; BLOOD ANALYSIS; CALCIUM BLOOD LEVEL; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; COCHRANE LIBRARY; DISEASE MARKER; DISEASE SEVERITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; MEDICAL LITERATURE; MEDLINE; NATURAL KILLER CELL; NEUTROPHIL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; RISK ASSESSMENT; THROMBOCYTOSIS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR NECROSIS; URINALYSIS; VALIDATION PROCESS;

CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MODELS, BIOLOGICAL; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; SEX FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 80052265588     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.06.041     Document Type: Review

References (197)

1. G. Lughezzani, C. Jeldres, and H. Isbarn Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis J Urol 182 2009 1287 1293
2. P.I. Karakiewicz, Q.-D. Trinh, and N. Bhojani Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival Eur Urol 51 2007 1616 1624 (Pubitemid 46634745)
3. P. Elson, R. Witte, and D.L. Trump Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma Cancer Res 48 1988 7310 7313 (Pubitemid 19014022)
4. R.J. Motzer, M. Mazumdar, and J. Bacik Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540 (Pubitemid 29368255)
5. R.J. Motzer, J. Bacik, and B.A. Murphy Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289 296 (Pubitemid 34032623)
6. R.J. Motzer, J. Bacik, and L.H. Schwartz Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma J Clin Oncol 22 2004 454 463 (Pubitemid 41079774)
7. T.M. Mekhail, R.M. Abou-Jawde, and G. Boumerhi Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma J Clin Oncol 23 2005 832 841 (Pubitemid 46224183)
8. B. Escudier, T.K. Choueiri, and S. Oudard Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941 J Urol 178 2007 1901 1905 (Pubitemid 47538612)
9. S. Negrier, F. Gomez, and J.-Y. Douillard Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Franais d'Immunothérapie World J Urol 23 2005 161 165 (Pubitemid 41136036)
10. D.Y.C. Heng, W. Xie, and M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
11. P.I. Karakiewicz, M. Sun, and J. Bellmunt Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteria Eur Urol 60 2011 48 56
12. R.J. Motzer, R.M. Bukowski, and R.A. Figlin Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma Cancer 113 2008 1552 1558
13. T.K. Choueiri, J.A. Garcia, and P. Elson Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy Cancer 110 2007 543 550 (Pubitemid 47106142)
14. A. Zisman, A.J. Pantuck, and F. Dorey Improved prognostication of renal cell carcinoma using an integrated staging system J Clin Oncol 19 2001 1649 1657 (Pubitemid 32230864)
15. A. Zisman, A.J. Pantuck, and J. Wieder Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma J Clin Oncol 20 2002 4559 4566 (Pubitemid 35402959)
16. L. Cindolo, P. Chiodini, and C. Gallo Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy Cancer 113 2008 65 71 (Pubitemid 351976387)
17. L. Cindolo, J.-J. Patard, and P. Chiodini Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study Cancer 104 2005 1362 1371 (Pubitemid 41356151)
18. V. Ficarra, G. Novara, and A. Galfano The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma BJU Int 103 2009 165 170
19. A. Galfano, G. Novara, and M. Iafrate Mathematical models for prognostic prediction in patients with renal cell carcinoma Urol Int 80 2008 113 123 (Pubitemid 351440502)
20. Z. Liu, J. Lv, and K. Ding Validation of the current prognostic models for nonmetastatic renal cell carcinoma after nephrectomy in Chinese population: a 15-year single center experience Int J Urol 16 2009 268 273
21. J.-J. Patard, E. Leray, and L. Cindolo Multi-institutional validation of a symptom based classification for renal cell carcinoma J Urol 172 2004 858 862 (Pubitemid 39096407)
22. M.-H. Tan, R. Kanesvaran, and H. Li Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma Urology 75 2010 1365 1370
23. P.I. Karakiewicz, A. Briganti, and F.K.-H. Chun Multi-institutional validation of a new renal cancer-specific survival nomogram J Clin Oncol 25 2007 1316 1322 (Pubitemid 46706877)
24. P.I. Karakiewicz, N. Suardi, and U. Capitanio A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma Eur Urol 55 2009 287 295
25. L. Cindolo, A. de la Taille, and G. Messina A preoperative clinical prognostic model for non-metastatic renal cell carcinoma BJU Int 92 2003 901 905 (Pubitemid 37548262)
26. O. Yaycioglu, W.W. Roberts, and T. Chan Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model Urology 58 2001 141 145 (Pubitemid 32728040)
27. G.V. Raj, R.H. Thompson, and B.C. Leibovich Preoperative nomogram predicting 12-year probability of metastatic renal cancer J Urol 179 2008 2146 2151 discussion 2151
28. M.W. Kattan, V. Reuter, and R.J. Motzer A postoperative prognostic nomogram for renal cell carcinoma J Urol 166 2001 63 67 (Pubitemid 32565343)
29. A.S. Parker, B.C. Leibovich, and C.M. Lohse Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma Cancer 115 2009 2092 2103
30. I. Frank, M.L. Blute, and J.C. Cheville An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score J Urol 168 2002 2395 2400 (Pubitemid 35402623)
31. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134 (Pubitemid 46089673)
32. B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111 (Pubitemid 350296300)
33. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124 (Pubitemid 46089672)
34. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281 (Pubitemid 46849157)
35. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
36. M. Yao, M. Yoshida, and T. Kishida VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma J Natl Cancer Inst 94 2002 1569 1575 (Pubitemid 35277281)
37. P. Schraml, K. Struckmann, and F. Hatz VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma J Pathol 196 2002 186 193 (Pubitemid 34110900)
38. B.I. Rini, E. Jaeger, and V. Weinberg Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status BJU Int 98 2006 756 762 (Pubitemid 44368020)
39. Choueiri TK, Vaziri S, Rini B, et al. Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (RCC) [abstract 5012]. Proceedings from the the American Society of Clinical Oncology Conference; 2007; Chicago, IL, USA.
40. T. Hutson, I. Davis, and J. Machiels Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor [abstract 5046] J Clin Oncol 20 Suppl 2008 261s
41. T.K. Choueiri, S.A.J. Vaziri, and E. Jaeger von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma J Urol 180 2008 860 865 discussion 865-6
42. M.S. Wiesener, P.M. Münchenhagen, and I. Berger Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas Cancer Res 61 2001 5215 5222 (Pubitemid 32681556)
43. A. Lidgren, Y. Hedberg, and K. Grankvist The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma Clin Cancer Res 11 2005 1129 1135 (Pubitemid 40175762)
44. A. Lidgren, Y. Hedberg, and K. Grankvist Hypoxia-inducible factor 1α expression in renal cell carcinoma analyzed by tissue microarray Eur Urol 50 2006 1272 1277 (Pubitemid 44692925)
45. T. Klatte, D.B. Seligson, and S.B. Riggs Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma Clin Cancer Res 13 2007 7388 7393
46. P. Patel, R. Chadalavada, and N. Ishill Hypoxia-inducible factor (HIF) 1α and 2α levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC) [abstract 5008] J Clin Oncol 26 Suppl 2008
47. J.R. Gnarra, S. Zhou, and M.J. Merrill Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene Proc Natl Acad Sci U S A 93 1996 10589 10594 (Pubitemid 26333031)
48. G. Siemeister, K. Weindel, and K. Mohrs Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein Cancer Res 56 1996 2299 2301 (Pubitemid 26154077)
49. X. Na, G. Wu, and C.K. Ryan Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas J Urol 170 2003 588 592 (Pubitemid 36870265)
50. V. Paradis, N.B. Lagha, and L. Zeimoura Expression of vascular endothelial growth factor in renal cell carcinomas Virchows Arch 436 2000 351 356 (Pubitemid 30219233)
51. J. Jacobsen, K. Grankvist, and T. Rasmuson Expression of vascular endothelial growth factor protein in human renal cell carcinoma BJU Int 93 2004 297 302 (Pubitemid 38253573)
52. N. Rioux-Leclercq, P. Fergelot, and S. Zerrouki Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases Hum Pathol 38 2007 1489 1495 (Pubitemid 47418959)
53. E. Yildiz, G. Gokce, and H. Kilicarslan Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma BJU Int 93 2004 1087 1093 (Pubitemid 38758639)
54. D. Swinson, J. Jones, and D. Richardson Carbonic anhydrase IX expression, a novel surrogate marker for tumor hypoxia, is associated with a poor prognosis in non-small cell lung cancer J Clin Oncol 21 2003 473 482 (Pubitemid 46613490)
55. A. Driessen, W. Landuyt, and S. Pastorekova Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas Ann Surg 243 2006 334 340 (Pubitemid 43327764)
56. K. Maseide, R. Kandel, and R. Bell Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma Clin Cancer Res 10 2004 4464
57. T. Dorai, I.S. Sawczuk, and J. Pastorek Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: proposal of a unified hypothesis Cancer Invest 24 2006 754 779 (Pubitemid 44949880)
58. N.B. Phuoc, H. Ehara, and T. Gotoh Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma Oncol Rep 20 2008 525 530
59. M.H.T. Bui, D. Seligson, and K.-r. Han Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy Clin Cancer Res 9 2003 802 811 (Pubitemid 36182618)
60. J.-J. Patard, P. Fergelot, and P.I. Karakiewicz Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma Int J Cancer 123 2008 395 400 (Pubitemid 351842025)
61. M. Atkins, M. Regan, and D. McDermott Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer Clin Cancer Res 11 2005 3714 3721 (Pubitemid 40685588)
62. B.C. Leibovich, Y. Sheinin, and C.M. Lohse Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma J Clin Oncol 25 2007 4757 4764 (Pubitemid 350086478)
63. Health UNIo. The high-dose aldesleukin (IL-2) "select" trial for patients with metastatic renal cell carcinoma (SELECT).ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00554515.
64. Health UNIo. Monoclonal antibody therapy (Rencarex®) in treating patients who have undergone surgery for non-metastatic kidney cancer. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00087022.
65. D. Sarbassov, S. Ali, and D. Sabatini Growing roles for the mTOR pathway Curr Opin Cell Biol 17 2005 596 603 (Pubitemid 41540408)
66. M. Neshat, I. Mellinghoff, and C. Tran Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc Natl Acad Sci U S A 98 2001 10314 10319 (Pubitemid 32803017)
67. N. Hay, and N. Sonenberg Upstream and downstream of mTOR Genes Dev 18 2004 1926 1945 (Pubitemid 39071573)
68. A.J. Pantuck, D.B. Seligson, and T. Klatte Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy Cancer 109 2007 2257 2267 (Pubitemid 46801555)
69. D. Cho, S. Signoretti, and S. Dabora Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma Clin Cancer Rev 1 2007 85 91
70. C. Tanaka, T. O'Reilly, and J. Kovarik Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data J Clin Oncol 26 2008 1596
71. A. Toker, and M. Yoeli-Lerner Akt signaling and cancer: surviving but not moving on Cancer Res 66 2006 3963 3966
72. A. Horiguchi, M. Oya, and A. Uchida Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma J Urol 169 2003 710 713 (Pubitemid 36133028)
73. W. Brenner, G. Färber, and T. Herget Loss of tumor suppressor protein PTEN during renal carcinogenesis Int J Cancer 99 2002 53 57 (Pubitemid 34273197)
74. R.A. Figlin, P. de Souza, and D. McDermott Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha Cancer 115 2009 3651 3660
75. D.C. Altieri Survivin, versatile modulation of cell division and apoptosis in cancer Oncogene 22 2003 8581 8589 (Pubitemid 38019195)
76. S.F. Shariat, P.I. Karakiewicz, and G. Godoy Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study Clin Cancer Res 15 2009 7012 7019
77. S. Shariat, P. Karakiewcz, and G. Godoy Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study Clin Cancer Res 15 2009 7012 7019
78. S. Shariat, Y. Lotan, and H. Saboorian Survivin expression is associated with features of biologically aggressive prostate carcinoma Cancer 100 2004 751 757 (Pubitemid 38176853)
79. C. Mahotka, T. Krieg, and A. Krieg Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas Int J Cancer 100 2002 30 36 (Pubitemid 34602061)
80. R. Zamparese, G. Pannone, and A. Santoro Survivin expression in renal cell carcinoma Cancer Invest 26 2008 929 935
81. A.S. Parker, F. Kosari, and C.M. Lohse High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma Cancer 107 2006 37 45 (Pubitemid 43939028)
82. S. Kuerbitz, B. Plunkett, and W. Walsh Wild type p53 is a cell cycle checkpoint determinant following irradiation Proc Natl Acad Sci U S A 89 1992 7491
83. D.P. Lane, and S. Benchimol p53: oncogene or anti-oncogene? Genes Dev 4 1990 1 8
84. S. Shariat, H. Tokunaga, and J. Zhou p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer J Clin Oncol 22 2004 1014 1024 (Pubitemid 41095033)
85. R. Zigeuner, M. Ratschek, and P. Rehak Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue Urology 63 2004 651 655 (Pubitemid 38479402)
86. H.L. Kim, D. Seligson, and X. Liu Using protein expressions to predict survival in clear cell renal carcinoma Clin Cancer Res 10 2004 5464 5471 (Pubitemid 39100484)
87. C. Girgin, H. Tarhan, and M. Hekimgil P53 mutations and other prognostic factors of renal cell carcinoma Urol Int 66 2001 78 83 (Pubitemid 32172972)
88. B. Kallakury, S. Karikehalli, and A. Haholu Increased expression of matrix metalloproteinnases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma Clin Cancer Res 7 2001 3113 3119 (Pubitemid 32963832)
89. N. Kawata, Y. Nagane, and T. Igarashi Strong significant correlation between MMP-9 and systemic symptoms in patients with localized renal cell carcinoma Urology 68 2006 523 527 (Pubitemid 44436510)
90. A. Kugler, B. Hemmerlein, and P. Thelen Expression of metalloproteinnase 2 and 9 and their inhibitors in renal cell carcinoma J Urol 160 1998 1914 1918 (Pubitemid 128746786)
91. S. Curran, and G.I. Murray Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis Eur J Cancer 36 2000 1621 1630 (Pubitemid 30616366)
92. Z. Jiang, P. Chu, and B. Woda Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study Lancet Oncol 7 2006 556 564 (Pubitemid 43923666)
93. N. Hoffman, Y. Sheinin, and C. Lohse External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma Cancer 112 2008 1471 1479 (Pubitemid 351441159)
94. Z. Jiang, P. Chu, and B. Woda Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas Clin Cancer Res 14 2008 5579 5584
95. V. Margulis, Y. Lotan, and P. Karakiewicz Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer J Natl Cancer Inst 101 2009 114 119
96. J.S. Lam, O. Shvarts, and J.W. Said Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma Cancer 103 2005 2517 2525 (Pubitemid 40800530)
97. T.J. Dudderidge, K. Stoeber, and M. Loddo Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma Clin Cancer Res 11 2005 2510 2517 (Pubitemid 40569447)
98. M.H.T. Bui, H. Visapaa, and D. Seligson Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma J Urol 171 2004 2461 2466 (Pubitemid 38625515)
99. T. Klatte, D.B. Seligson, and J. Larochelle Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy Cancer Epidemiol Biomarkers Prev 18 2009 894 900
100. M.K. Tollefson, R.H. Thompson, and Y. Sheinin Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other Cancer 110 2007 783 790 (Pubitemid 47257655)
101. H. Visapää, M. Bui, and Y. Huang Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma Urology 61 2003 845 850 (Pubitemid 36384994)
102. G. Hofmockel, P. Tsatalpas, and H. Müller Significance of conventional and new prognostic factors for locally confined renal cell carcinoma Cancer 76 1995 296 306
103. R.G. Anderson The caveolae membrane system Annu Rev Biochem 67 1998 199 225 (Pubitemid 28411129)
104. C.-C. Ho, P.-H. Huang, and H.-Y. Huang Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation Am J Pathol 161 2002 1647 1656 (Pubitemid 35265524)
105. L. Li, G. Yang, and S. Ebara Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells Cancer Res 61 2001 4386 4392 (Pubitemid 32685764)
106. P.H. Rajjayabun, S. Garg, and G.C. Durkan Caveolin-1 expression is associated with high-grade bladder cancer Urology 58 2001 811 814
107. M. Suzuoki, M. Miyamoto, and K. Kato Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma Br J Cancer 87 2002 1140 1144 (Pubitemid 35418110)
108. K. Kato, Y. Hida, and M. Miyamoto Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage Cancer 94 2002 929 933 (Pubitemid 34150846)
109. J. Karam, Y. Lotan, and C. Roehrborn Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence Prostate 67 2007 614 622 (Pubitemid 46685281)
110. L. Campbell, B. Jasani, and K. Edwards Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma Br J Cancer 98 2008 931 940 (Pubitemid 351341603)
111. H.J. Joo, D.K. Oh, and Y.S. Kim Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma BJU Int 93 2004 291 296 (Pubitemid 38253572)
112. B.C. Leibovich, J.C. Cheville, and C.M. Lohse A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials J Urol 174 2005 1759 1763 discussion 1763 (Pubitemid 41546928)
113. H. Isbarn, J. Patard, and G. Lughezzani Limited prognostic value of tumor necrosis in patients with renal cell carcinoma Urology 75 2010 1378 1384
114. M.D. Katz, M.F. Serrano, and R.L. Grubb Percent microscopic tumor necrosis and survival after curative surgery for renal cell carcinoma J Urol 183 2010 909 914
115. T. Klatte, J.W. Said, and M. de Martino Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification J Urol 181 2009 1558 1564 discussion 1563-4
116. R.H. Thompson, B.C. Leibovich, and C.M. Lohse Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score J Urol 177 2007 477 480 (Pubitemid 46054015)
117. T.V. Johnson, A. Abbasi, and A. Owen-Smith Absolute preoperative C-Reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma J Urol 183 2010 480 485
118. P.I. Karakiewicz, G.C. Hutterer, and Q.-D. Trinh C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients Cancer 110 2007 1241 1247 (Pubitemid 47435594)
119. Y. Iimura, K. Saito, and Y. Fujii Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score J Urol 181 2009 1004 1012 discussion 1012
120. L. Liu, J. Qian, and H. Singh Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis Arch Pathol Lab Med 131 2007 1290 1297 (Pubitemid 47257641)
121. J.D. Khoury, N.A. Abrahams, and H.S. Levin The utility of epithelial membrane antigen and vimentin in the diagnosis of chromophobe renal cell carcinoma Ann Diagn Pathol 6 2002 154 158 (Pubitemid 34700852)
122. A.K. Avery, J. Beckstead, and A.A. Renshaw Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms Am J Surg Pathol 24 2000 203 210 (Pubitemid 30078709)
123. A.N. Young, M.B. Amin, and C.S. Moreno Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers Am J Pathol 158 2001 1639 1651 (Pubitemid 32422929)
124. H. Moch, P. Schraml, and L. Bubendorf High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma Am J Pathol 154 1999 981 986 (Pubitemid 29169731)
125. A.A. Williams, J.P.T. Higgins, and H. Zhao CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma BMC Clin Pathol 9 2009 9
126. R. Zigeuner, N. Droschl, and V. Tauber Biologic significance of fascin expression in clear cell renal cell carcinoma: systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique Urology 68 2006 518 522 (Pubitemid 44436491)
127. J. Jin, C. Yu, and G. Sun Increasing expression of fascin in renal cell carcinoma associated with clinicopathological parameters of aggressiveness Histopathology 21 2006 1287 1293 (Pubitemid 44614510)
128. P.I. Karakiewicz, Q.-D. Trinh, and J.S. Lam Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality Eur Urol 52 2007 1428 1437 (Pubitemid 47445975)
129. N. Symbas, M. Townsend, and R. El-Galley Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma BJU Int 86 2000 203 207 (Pubitemid 30621216)
130. R. Suppiah, P.E. Shaheen, and P. Elson Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma Cancer 107 2006 1793 1800 (Pubitemid 44582948)
131. S. O'Keefe, F. Marshall, and M. Issa Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy J Urol 168 2002 1378 1380 (Pubitemid 35034126)
132. K. Bensalah, E. Leray, and P. Fergelot Prognostic value of thrombocytosis in renal cell carcinoma J Urol 175 2006 859 863 (Pubitemid 43199997)
133. J. Atzpodien, P. Royston, and T. Wandert Metastatic renal carcinoma comprehensive prognostic system Br J Cancer 88 2003 348 353 (Pubitemid 36308143)
134. S. Négrier, B. Escudier, and F. Gomez Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Franais d'Immunothérapie Ann Oncol 13 2002 1460 1468
135. F. Donskov, M. Hokland, and N. Marcussen Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma - results from a randomised phase II trial Br J Cancer 94 2006 218 226 (Pubitemid 43151539)
136. H.K. Jensen, F. Donskov, and N. Marcussen Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma J Clin Oncol 27 2009 4709 4717
137. B.C. Leibovich, K.-R. Han, and M.H.T. Bui Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials Cancer 98 2003 2566 2575 (Pubitemid 37509519)
138. J. Jacobsen, T. Rasmuson, and K. Grankvist Vascular endothelial growth factor as prognostic factor in renal cell carcinoma J Urol 163 2000 343 347
139. T. Klatte, M. Böhm, and T. Nelius Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma BJU Int 100 2007 209 214 (Pubitemid 46878551)
140. S. Negrier, D. Perol, and C. Menetrier-Caux Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 - from the Groupe Francais d'Immunotherapie J Clin Oncol 22 2004 2371 2378 (Pubitemid 41115394)
141. L. Schips, O. Dalpiaz, and K. Lipsky Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group Eur Urol 51 2007 168 174 discussion 174 (Pubitemid 44821523)
142. S. Shariat, V. Anwuri, and D. Lamb Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy J Clin Oncol 22 2004 1655 1663 (Pubitemid 41079804)
143. S.E. Deprimo, C.L. Bello, and J. Smeraglia Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins J Transl Med 5 2007 32
144. C. Porta, J. Bellmunt, and T. Eisen Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma Cancer Treat Rev 36 2010 16 23
145. B.I. Rini, M.D. Michaelson, and J.E. Rosenberg Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma J Clin Oncol 26 2008 3743 3748
146. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
147. J. Ramankulov, M. Lein, and M. Johannsen Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma Cancer Lett 269 2008 85 92
148. K. Junker, F. von Eggeling, and J. Muller Identification of biomarkers and therapeutic targets for renal cell cancer using ProteinChip technology Urologe A 45 2006 305 306 8, 210-2
149. J. Závada, Z. Závadová, and M. Zat'ovicová Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients Br J Cancer 89 2003 1067 1071 (Pubitemid 37239213)
150. J.M. McKiernan, R. Buttyan, and N.H. Bander The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9 Cancer 86 1999 492 497 (Pubitemid 29347412)
151. G.X. Zhou, J. Ireland, and P. Rayman Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials Urology 75 2010 257 261
152. G. Li, G. Feng, and A. Gentil-Perret Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer J Urol 180 2008 510 513 discussion 513-4
153. S.M. Gilbert, J.M. Whitson, and M. Mansukhani Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors Urology 67 2006 942 945 (Pubitemid 43956430)
154. L. Kjeldsen, A. Johnsen, and H. Sengelov Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase J Biol Chem 268 1993 10425 10432 (Pubitemid 23150227)
155. T. Matthaeus, E. Schulze-Lohoff, and T. Ichimura Co-regulation of neutrophil gelatinase-associated lipocalin and matrix metalloproteinase-9 in the postischemic rat kidney J Am Soc Nephrol 12 2001 787A
156. K. Mori, H. Thomas Lee, and D. Rapoport Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury J Clin Invest 115 2005 610
157. Z. Tong, X. Wu, and D. Ovcharenko Neutrophil gelatinase associated lipocalin as a survival factor Biochem J 391 2005 441 448 (Pubitemid 41532443)
158. C. Porta, C. Paglino, and M. De Amici Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib Kidney Int 77 2010 809 815
159. T. Rasmuson, K. Grankvist, and J. Jacobsen Serum insulin-like growth factor-1 is an independent predictor of prognosis in patients with renal cell carcinoma Acta Oncol 43 2004 744 748 (Pubitemid 40066017)
160. Y. Lotan, U. Capitanio, and S.F. Shariat Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection BJU Int 103 2009 1368 1374
161. S. Shariat, C. Zippe, and G. Ludecke Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder J Urol 173 2005 1518 1525 (Pubitemid 40524761)
162. G.C. Hutterer, P.I. Karakiewicz, and C. Zippe Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma BJU Int 101 2008 561 565 (Pubitemid 351199283)
163. G. Ozer, M. Altinel, and B. Kocak Value of urinary NMP-22 in patients with renal cell carcinoma Urology 60 2002 593 597 (Pubitemid 35246439)
164. K. Kaya, S. Ayan, and G. Gokce Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma Scand J Urol Nephrol 39 2005 25 29 (Pubitemid 40380439)
165. S. Huang, E. Rhee, and H. Patel Urinary NMP22 and renal cell carcinoma Urology 55 2000 227 230 (Pubitemid 30069921)
166. L. Van den Hove, S. Van Gool, and H. Van Poppel Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma Clin Exp Immulol 109 1997 501 509 (Pubitemid 27402320)
167. E. Bromwich, P. McArdle, and K. Canna The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer Br J Cancer 17 2003 1906 1908 (Pubitemid 37533268)
168. T. Igarashi, S. Murakami, and H. Takahashi Changes on distribution of CD4+/CD45RA- and CD8+/CD11- cells in tumor-infiltrating lymphocytes of renal cell carcinoma associated with tumor progression Eur Urol 22 1992 323 328 (Pubitemid 23012862)
169. B. Banner, J. Burnham, and R. Banhson Immunophenotypic markers in renal cell carcinoma Mod Pathol 3 1990 129 134
170. P. Kolbeck, F. Kaveggia, and S. Johansson The relationships among tumor-infiltrating lymphocytes, histopathologic findings, and long-term clinical follow-up in renal cell carcinoma Mod Pathol 5 1992 420 425
171. D. Kowalczyk, W. Skorupski, and Z. Kwaias Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma Br J Urol 80 1997 543 547 (Pubitemid 28316374)
172. O. Nakano, M. Sato, and Y. Naito Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity Cancer Res 61 2001 5132 5136 (Pubitemid 32681545)
173. J.M. Cózar, J. Canton, and M. Tallada Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas Cancer Immunol Immunother 54 2005 858 866 (Pubitemid 40991328)
174. F. Donskov, and H. von der Maase Impact of immune parameters on long-term survival in metastatic renal cell carcinoma J Clin Oncol 24 2006 1997 2005 (Pubitemid 46622107)
175. H. Kitamura, I. Honma, and T. Torigoe Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma J Urol 177 2007 1269 1272 (Pubitemid 46435986)
176. M. Beyer, and J. Schultze Regulatory T cells in cancer Blood 108 2006 804 811 (Pubitemid 44154611)
177. S.A. Siddiqui, X. Frigola, and S. Bonne-Annee Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma Clin Cancer Res 13 2007 2075 2081 (Pubitemid 46649875)
178. J.F. Li, Y.W. Chu, and G.M. Wang The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma BJU Int 103 2009 399 405
179. H. Dong, G. Zhu, and K. Tamada B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat Med 5 1999 1365 1369
180. H. Dong, S.E. Strome, and D.R. Salomao Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 2002 793 800
181. S. Wintterle, B. Schreiner, and M. Mitsdoerffer Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis Cancer Res 63 2003 7462 7467 (Pubitemid 37413489)
182. C. Blank, I. Brown, and A.C. Peterson PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells Cancer Res 64 2004 1140 1145 (Pubitemid 38176921)
183. R.H. Thompson, S.M. Kuntz, and B.C. Leibovich Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up Cancer Res 66 2006 3381 3385
184. R. Thompson, M. Gillett, and J. Cheveille Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target Proc Natl Acad Sci U S A 101 2004 17174 17179 (Pubitemid 39627793)
185. R. Thompson, M. Gillett, and J. Cheville Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma Cancer 104 2005 2084 2091 (Pubitemid 41579953)
186. A.E. Krambeck, H. Dong, and R.H. Thompson Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma Clin Cancer Res 13 2007 1749 1756 (Pubitemid 46952941)
187. H.L. Kim, D. Seligson, and X. Liu Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma J Urol 173 2005 1496 1501 (Pubitemid 40524757)
188. S. Patil, R.A. Figlin, and T. Hutson Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC) [abstract 1542] J Clin Oncol 27 Suppl 2009
189. P.I. Karakiewicz, N. Suardi, and U. Capitanio Conditional survival predictions after nephrectomy for renal cell carcinoma J Urol 182 2009 2607 2612
190. B.R. Lane, M.K. Samplaski, and B.R. Herts Renal mass biopsy - a renaissance? J Urol 179 2008 20 27
191. J.M. Hollingsworth, D.C. Miller, and S. Daignault Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis Cancer 109 2007 1763 1768 (Pubitemid 46668538)
192. G.C. Hutterer, J.-J. Patard, and P. Perrotte Patients with renal cell carcinoma nodal metastases can be accurately identified: external validation of a new nomogram Int J Cancer 121 2007 2556 2561 (Pubitemid 350022428)
193. G.C. Hutterer, J.-J. Patard, and C. Jeldres Patients with distant metastases from renal cell carcinoma can be accurately identified: external validation of a new nomogram BJU Int 101 2008 39 43 (Pubitemid 350233554)
194. A. Kutikov, B.L. Egleston, and Y.-N. Wong Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram J Clin Oncol 28 2010 311 317
195. I. Frank, M.L. Blute, and J.C. Cheville A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma J Urol 170 2003 2225 2232 (Pubitemid 37413963)
196. M. Sorbellini, M.W. Kattan, and M.E. Snyder A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma J Urol 173 2005 48 51 (Pubitemid 39627669)
197. J.S. Lam, O. Shvarts, and J.T. Leppert Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system J Urol 174 2005 466 472 discussion 472; quiz 801 (Pubitemid 40981575)